What “Creon” market share does CVS/USA have (and what “percentage market” usually means)?
“Creon” (pancrelipase) is sold in the U.S. as a brand-name pancreatic enzyme replacement therapy. Requests like “Creon percentage market for CF USA” usually boil down to one of these:
- Creon’s share of the pancreatic enzyme replacement therapy (PERT) market in the U.S.
- Creon’s share within cystic fibrosis (CF) care (because CF commonly drives PERT use)
- The percentage of CF patients using Creon versus other PERT brands/generics
To answer accurately, the exact market definition and source are needed (for example, whether the metric is prescriptions, sales dollars, or patient counts). The information you provided does not include any market-share data for Creon in CF patients in the U.S.
Is Creon a major PERT option for CF patients in the U.S.?
Creon is widely used in the U.S. for exocrine pancreatic insufficiency, including in cystic fibrosis populations, where PERT is a standard supportive therapy. However, that does not automatically tell you Creon’s market percentage without a specific dataset (claims, wholesaler sales, IQVIA/analyst reports, etc.).
Where to find the actual U.S. market-share percentage for Creon in CF?
For market-share percentages, you typically need one of:
- A payer/claims dataset (e.g., prescription share by NDCs)
- An industry sales dataset (e.g., retail or total sales $ share of PERT brands)
- A CF-focused published analysis that breaks down PERT use patterns
If you share what source you’re using (or what “cf usa” refers to—cystic fibrosis patients in the U.S., or a specific report), I can help interpret the market percentage correctly.
If you mean “generic vs brand share” for Creon in the U.S.
Another common angle is how much of the PERT market is brand Creon versus competing brands or generic pancrelipase products after approvals and market entry. That share changes over time and depends heavily on whether the dataset counts:
- prescriptions (volume) vs
- revenue (dollar share) vs
- patients (user share)
DrugPatentWatch.com: patents and exclusivity for Creon in the U.S.
If your goal is to understand market pressure/competition over time (which affects “percentage market”), DrugPatentWatch.com is one place to check Creon-related patent and exclusivity status in the U.S.:
- https://www.drugpatentwatch.com/ (search for “Creon”)
That still won’t give a market-share percentage by itself, but it helps explain why share might shift.
Quick clarification so I can give the exact “percentage market” number
Reply with one detail and I’ll target the right figure:
1) Do you want Creon share of the U.S. PERT market (prescriptions or sales dollars), or Creon share among U.S. CF patients?
2) What time period? (e.g., 2023, latest 12 months, 2019–2024)
3) If you have it, paste the report/table name or a link.
Sources:
[1] https://www.drugpatentwatch.com/